Combination of three adjuvants enhances the immunogenicity of a recombinant protein containing the CTL epitopes of non-structural proteins of hepatitis C virus

Kuprianov, Victor V.; Николаева, Л. И.; Zykova, A.; Dedova, A. V.; Гришечкин, А. Е.; Kapustin, I. V.; Kotlyarov, Roman Y.; Ravin, Nikolai V.

doi:10.1016/j.virusres.2020.197984

Cited by 7 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To significantly improve the immunogenicity and antigenicity of the S7M8 vaccine, PADRE helper peptide, TLR2 agonist Pam2Cys and TLR4 agonist RS-09 were incorporated into the vaccine design. PADRE, an epitope peptide derived from HLA-DR and tetanus toxin, is commonly used as a helper peptide to induce Th1 cell polarization [79] . In addition, the PADRE peptide can bind to various types of MHC-II alleles to enhance the immune response to vaccines [80] .…”

Section: Discussionmentioning

confidence: 99%

Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis

Jiang

Liu

Xue

et al. 2023

International Immunopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis

Jiang

Liu

Xue

et al. 2023

International Immunopharmacology

View full text Add to dashboard Cite

“…Additionally, we included the PADRE helper peptide in the MEV. PADRE is an epitope peptide that can bind to HLA-DR and induce initial helper T lymphocyte differentiation to the Th1 type through enhanced IFN-γ secretion, thereby improving the efficiency of immune cell recognition and response to MHCII-restricted epitopes [70,71]. The incorporation of these elements in the C624P vaccine design represents a promising approach to enhance TLR-mediated immunity and improve the efficacy of the vaccine in preventing LTBI.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to its ability to activate innate immune cells, the C624P vaccine was designed with TLR2 and TLR4 agonists, enabling the vaccine to target antigen-presenting cells such as macrophages specifically. The inclusion of the PADRE helper peptide in the vaccine further enhances its efficiency by inducing an initial helper T-lymphocyte differentiation to the Th1 type through the secretion of IFN-γ, thereby improving the efficiency of immune cell recognition and response to MHCII-restricted epitopes [70,71]. These design features are critical to the vaccine's efficacy and may contribute to a protective immune response against M. tuberculosis infection.…”

Section: Discussionmentioning

confidence: 99%

Design and development of a multi‐epitope vaccine for the prevention of latent tuberculosis infection

Jiang,

Wang,

Wang

et al. 2023

Medicine Advances

View full text Add to dashboard Cite

BackgroundLatent tuberculosis infection (LTBI) often progresses to active tuberculosis, necessitating the development of novel vaccine to prevent LTBI. In this study, we aimed to design a Mycobacterium tuberculosis (M. tuberculosis) vaccine that could elicit a potent immune response to prevent LTBI.MethodsWe used bioinformatics and immunoinformatics techniques to develop a multi‐epitope vaccine (MEV) called C624P. The vaccine contained six cytotoxic T lymphocytes (CTL), two helper T lymphocytes (HTL), and four B‐cell epitopes derived from six antigens associated with LTBI and the Mycobacterium tuberculosis region of difference. We added Toll‐like receptor (TLR) agonists and PADRE peptide to the MEV to enhance its immunogenicity. We then analyzed the C624P vaccine's physical and chemical properties, spatial structure, molecular docking with TLRs, and immunological features.ResultsThe C624P vaccine displayed good antigenicity and immunogenicity scores of 0.901398 and 3.65609, respectively. The vaccine structure was stable, with 42.82% α‐helix content, a Z‐value of −7.84, and a favored Ramachandran plot area of 85.84% after majorization. Molecular docking analysis showed that the C624P vaccine could bind tightly to TLR2 (−1011.0 kcal/mol) and TLR4 (−941.4 kcal/mol). Furthermore, the C624P vaccine effectively stimulated T and B lymphocytes, resulting in high levels of Th1 cytokines such as IFN‐γ and IL‐2.ConclusionsThe C624P vaccine represents a promising MEV for preventing LTBI. The vaccine's good antigenicity, immunogenicity, stability, and ability to activate immune responses suggest its effectiveness in preventing LTBI. Our study demonstrated the utility of bioinformatics and immunoinformatics techniques in designing safe and effective tuberculosis vaccines.

show abstract

“…Kuprianov et al designed a recombinant HCV polyprotein vaccine consisting of cytotoxic T-lymphocyte epitopes of the NS3, NS4A/B, and NS5A proteins fused with Th pan HLA-DR-binding epitope (PADRE), the lipopeptide from Neisseria meningiditis , and IL-2 as adjuvants. This vaccine showed high immunogenicity, since it enhanced DCs stimulation and polarized them into a Th1 response, inducing IFN-γ and T-lymphocytes proliferation in BALB/c mice [ 160 ].…”

Section: Adjuvants In Hcv Vaccinesmentioning

confidence: 99%

Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants

2020

View full text Add to dashboard Cite

Despite successful treatments, hepatitis C virus (HCV) infections continue to be a significant world health problem. High treatment costs, the high number of undiagnosed individuals, and the difficulty to access to treatment, particularly in marginalized susceptible populations, make it improbable to achieve the global control of the virus in the absence of an effective preventive vaccine. Current vaccine development is mostly focused on weakly immunogenic subunits, such as surface glycoproteins or non-structural proteins, in the case of HCV. Adjuvants are critical components of vaccine formulations that increase immunogenic performance. As we learn more information about how adjuvants work, it is becoming clear that proper stimulation of innate immunity is crucial to achieving a successful immunization. Several hepatic cell types participate in the early innate immune response and the subsequent inflammation and activation of the adaptive response, principally hepatocytes, and antigen-presenting cells (Kupffer cells, and dendritic cells). Innate pattern recognition receptors on these cells, mainly toll-like receptors, are targets for new promising adjuvants. Moreover, complex adjuvants that stimulate different components of the innate immunity are showing encouraging results and are being incorporated in current vaccines. Recent studies on HCV-vaccine adjuvants have shown that the induction of a strong T- and B-cell immune response might be enhanced by choosing the right adjuvant.

show abstract

Combination of three adjuvants enhances the immunogenicity of a recombinant protein containing the CTL epitopes of non-structural proteins of hepatitis C virus

Cited by 7 publications

References 41 publications

Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis

Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis

Design and development of a multi‐epitope vaccine for the prevention of latent tuberculosis infection

Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants

Contact Info

Product

Resources

About